Mary Wilson
Well-known member
medRxiv preprint
doi: https://doi.org/10.1101/2021.08.22.21262168; this version posted August 30, 2021.
George Ronald Nahass*1, Rachel E. Salomon-Shulman*1, Grace Blacker1, Kazim Haider1, Rich Brotherton2, Kristine Teague1, Ying Ying Yiu1, Rachel E. Brewer1, Sarah Danielle Galloway1, Paige Hansen1,11, Gabriel Marquez-Arreguin1, Salma Sheikh-Mohamed3, Gary Y.C. Chao3, Baweleta Isho3, Evan Do4, Iris Chang4, Theo Snow4, Alexandra S. Lee4, STANFORD COVID-19 BIOBANK5, Monali Manohar4, Samuel Yang6, Andra L. Blomkalns6, Angela J, Rogers7, Allison McGeer8, Anne-Claude Gingras8,9, Sharon Straus10, Phillip Grant7, Kari C. Nadeau4, Catherine A. Blish7, Jennifer L. Gommerman3, Erin C. Sanders1,11, Irving L. Weissman1, Michal Caspi Tal1
ABSTRACT
Vaccination induced antibody and T-cell immune responses are important for systemic protection from COVID-19. Because SARS-CoV-2 infects and is transmitted by oral-pharyngeal mucosa, we wished to test mucosal antibodies elicited by natural infection or intramuscular vaccine injection. In a non-randomized observational study, we measured antibodies against the SARS-CoV-2 RBD in plasma and saliva from convalescent or vaccinated individuals and tested their neutralizing potential using a replication competent rVSV-eGFP-SARS-CoV-2. We found IgG and IgA anti-RBD antibodies as well as neutralizing activity in convalescent plasma and saliva. Two doses of mRNA vaccination (BNT162b2 or mRNA-1273) induced high levels of IgG anti-RBD in saliva, a subset of whom also had IgA, and significant neutralizing activity. We detected anti-RBD IgG and IgA with significant neutralizing potential in the plasma of single dose Ad26.COV2.S vaccinated individuals, and we detected slight amounts of anti-RBD antibodies in matched saliva. The role of salivary antibodies in protection against SARS-CoV-2 infection is unknown and merits further investigation. This study was not designed to, nor did it study the full kinetics of the antibody response or protection from infection, nor did it address variants of SARS-CoV-2.
https://www.medrxiv.org/content/10.1101/2021.08.22.21262168v1.full.pdf
doi: https://doi.org/10.1101/2021.08.22.21262168; this version posted August 30, 2021.
George Ronald Nahass*1, Rachel E. Salomon-Shulman*1, Grace Blacker1, Kazim Haider1, Rich Brotherton2, Kristine Teague1, Ying Ying Yiu1, Rachel E. Brewer1, Sarah Danielle Galloway1, Paige Hansen1,11, Gabriel Marquez-Arreguin1, Salma Sheikh-Mohamed3, Gary Y.C. Chao3, Baweleta Isho3, Evan Do4, Iris Chang4, Theo Snow4, Alexandra S. Lee4, STANFORD COVID-19 BIOBANK5, Monali Manohar4, Samuel Yang6, Andra L. Blomkalns6, Angela J, Rogers7, Allison McGeer8, Anne-Claude Gingras8,9, Sharon Straus10, Phillip Grant7, Kari C. Nadeau4, Catherine A. Blish7, Jennifer L. Gommerman3, Erin C. Sanders1,11, Irving L. Weissman1, Michal Caspi Tal1
ABSTRACT
Vaccination induced antibody and T-cell immune responses are important for systemic protection from COVID-19. Because SARS-CoV-2 infects and is transmitted by oral-pharyngeal mucosa, we wished to test mucosal antibodies elicited by natural infection or intramuscular vaccine injection. In a non-randomized observational study, we measured antibodies against the SARS-CoV-2 RBD in plasma and saliva from convalescent or vaccinated individuals and tested their neutralizing potential using a replication competent rVSV-eGFP-SARS-CoV-2. We found IgG and IgA anti-RBD antibodies as well as neutralizing activity in convalescent plasma and saliva. Two doses of mRNA vaccination (BNT162b2 or mRNA-1273) induced high levels of IgG anti-RBD in saliva, a subset of whom also had IgA, and significant neutralizing activity. We detected anti-RBD IgG and IgA with significant neutralizing potential in the plasma of single dose Ad26.COV2.S vaccinated individuals, and we detected slight amounts of anti-RBD antibodies in matched saliva. The role of salivary antibodies in protection against SARS-CoV-2 infection is unknown and merits further investigation. This study was not designed to, nor did it study the full kinetics of the antibody response or protection from infection, nor did it address variants of SARS-CoV-2.
https://www.medrxiv.org/content/10.1101/2021.08.22.21262168v1.full.pdf